StreetInsider.com News Articles

TD Cowen Starts Teva Pharma (TEVA) at Buy

Thu, 01 Oct 2026 05:30:25 -0400

(Updated - October 1, 2026 5:30 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $55.00.

The analyst comments "Teva is a global biopharma company that leverages both a base of generic/biosimilar products and a growing therapeutics pipeline. Approved agents across neuropsychiatry and CNS indications are set for continued growth, bolstered by potential additional nearterm product launches (ecopipam and olanzapine LAI) and compelling pipeline advancements (duvakitug, TEV-408, DARI). Our NPVbased PT is $55."

For an analyst ratings summary and ratings history on Teva Pharma click here. For more

TD Cowen Starts Teva Pharma (TEVA) at Buy

Thu, 01 Oct 2026 05:30:25 -0400

(Updated - October 1, 2026 5:30 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $55.00.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more

TD Cowen Starts Teva Pharma (TEVA) at Buy

Thu, 01 Oct 2026 05:30:25 -0400

(Updated - October 1, 2026 5:30 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $55.00.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more

TD Cowen Starts Teva Pharma (TEVA) at Buy

Thu, 01 Oct 2026 05:30:25 -0400

(Updated - October 1, 2026 5:30 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $55.00.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more

Samsung Bioepis and Teva expand biosimilar partnership to six candidates

Thu, 01 Oct 2026 04:30:14 -0400

Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) have entered into a global license, development, and commercialization agreement covering up to six biosimilar candidates, according to a press release from the companies.

The agreement includes two confirmed investigational biosimilar candidates: SB41, referencing Fasenra® (benralizumab), and SB44, referencing Ilaris® (canakinumab), with an option for four additional assets. Samsung Bioepis will handle development, regulatory registration, and manufacturing, while Teva will manage commercialization in the United States, Europe, and Canada. The agreement includes an option to expand to other territories.

The two companies have an existing partnership that previously resulted

Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates

Thu, 01 Oct 2026 04:30:00 -0400

The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assets
The partnership will cover development and commercialization in the United States, Europe, and Canada, with an option to expand to other territories
The partnership brings together Samsung Bioepis’ development, regulatory and manufacturing capabilities with Teva’s global commercial reach to advance the investigational biosimilar candidates and help bring additional important treatment options to patients worldwide

INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)-- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and

Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates

Thu, 01 Oct 2026 04:30:00 -0400

The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assets
The partnership will cover development and commercialization in the United States, Europe, and Canada, with an option to expand to other territories
The partnership brings together Samsung Bioepis’ development, regulatory and manufacturing capabilities with Teva’s global commercial reach to advance the investigational biosimilar candidates and help bring additional important treatment options to patients worldwide

INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)-- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and

TAPI appoints Serge Rogasik as chief executive officer

Wed, 30 Sep 2026 16:32:13 -0400

TAPI (Technology & API Services), a producer of active pharmaceutical ingredients (APIs) based in Tel Aviv, Israel, has appointed Serge Rogasik as its Chief Executive Officer, according to a statement from the company.

Rogasik brings more than 25 years of experience in specialty ingredients, active ingredients, specialty chemicals, and life sciences. Most recently, he served as President and Chief Executive Officer of Kensing, a specialty ingredients company owned by One Rock Capital Partners, where he oversaw the integration of four acquisitions and expanded the company's global footprint. Prior to Kensing, he held leadership roles at Vantage Specialty Chemicals and Addivant, and

TAPI appoints Serge Rogasik as chief executive officer

Wed, 30 Sep 2026 16:32:13 -0400

TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness

Wed, 30 Sep 2026 16:32:00 -0400

TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global business that combines a broad API portfolio, deep scientific and technical capabilities, and an extensive global operations network serving customers worldwide.

“I am honored to join TAPI at such an important moment in its evolution," said Mr. Rogasik. "TAPI combines a unique set of capabilities, assets and talented people with a well-earned reputation as a trusted partner to customers worldwide. As the pharmaceutical industry increasingly

TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness

Wed, 30 Sep 2026 16:32:00 -0400

FDA approves Teva's Degevma as biosimilar to Xgeva

Mon, 28 Sep 2026 16:04:03 -0400

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration has approved DEGEVMA™ (denosumab-adet) as a biosimilar to Xgeva® (denosumab), according to a company statement.

DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone, and for the treatment of hypercalcemia of malignancy.

The approval marks Teva's second FDA-approved biosimilar in 2026. Combined with PONLIMSI™ (denosumab-adet), which received FDA approval in March 2026 as a biosimilar to Prolia® (denosumab), the two

FDA approves Teva's Degevma as biosimilar to Xgeva

Mon, 28 Sep 2026 16:04:03 -0400

Oppenheimer Starts Teva Pharma (TEVA) at Outperform

Wed, 23 Sep 2026 06:12:13 -0400

Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharma (NYSE: TEVA) with a Outperform rating and a price target of $50.00.

The analyst comments "We initiate coverage of Teva with an Outperform rating and $50 PT. Teva is entering the acceleration phase of its transformation, supported by ~$3.7B of expected 2026 sales from Austedo, Ajovy, and Uzedy, improving margins, and a multi-year innovative launch cycle. Positive TEV-’408 celiac data, Ecopipam Priority Review, and Duvakitug’s multi-indication potential strengthen the pipeline case. Meanwhile, biosimilar growth, full investment-grade status, refinancing, and direct NYSE trading reduce financial risk and broaden investor access. We believe investors

Oppenheimer Starts Teva Pharma (TEVA) at Outperform

Wed, 23 Sep 2026 06:12:13 -0400

Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharma (NYSE: TEVA) with a Outperform rating and a price target of $50.00.

Oppenheimer Starts Teva Pharma (TEVA) at Outperform

Wed, 23 Sep 2026 06:12:13 -0400

Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharma (NYSE: TEVA) with a Outperform rating and a price target of $50.00.

Oppenheimer Starts Teva Pharma (TEVA) at Outperform

Wed, 23 Sep 2026 06:12:13 -0400

Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharma (NYSE: TEVA) with a Outperform rating and a price target of $50.00.

Form 8-K TEVA PHARMACEUTICAL INDU For: Sep 14

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091843.html

Form 4 TEVA PHARMACEUTICAL INDU For: Sep 18 Filed by: Savage Brian

Tue, 22 Sep 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260922/27091740.html

Form 4 TEVA PHARMACEUTICAL INDU For: Sep 19 Filed by: MIGNONE ROBERTO

Tue, 22 Sep 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260922/27091333.html

Form 144 TEVA PHARMACEUTICAL INDU Filed by: Savage Brian

Mon, 21 Sep 2026 06:40:00 -0400

si-local-file:///var/storage/secattach/20260921/27082723.html

Form 144 TEVA PHARMACEUTICAL INDU Filed by: BRIDGER MANAGEMENT, LLC

Fri, 18 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260918/27081205.html

Teva shares Phase 3 data on once-monthly schizophrenia injection

Fri, 18 Sep 2026 16:30:56 -0400

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) presented post hoc data from the Phase 3 SOLARIS trial for its investigational drug TEV-'749, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for the treatment of schizophrenia in adults. The findings were presented at Psych Congress in New Orleans on Sept. 18, 2026.

In a post hoc analysis of the open-label period of the SOLARIS trial, 231 of 411 participants (56%) achieved stabilization across three dose groups of 318 mg, 425 mg, and 531 mg. Among those who achieved stabilization, only 10 (4%) experienced relapse. Of 183 participants treated for six or more months,

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophren

Fri, 18 Sep 2026 16:30:00 -0400

In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of participants receiving TEV-'749 for ≥ 6 months met criteria for remission
Treatment switch analyses provide clinical insights into maintaining established therapeutic ranges of olanzapine when initiating TEV-'749 from existing regimens
Ahead of the Q4 FDA anticipated approval decision, the growing body of science around TEV-'749 demonstrates Teva’s commitment to patient-centered innovation in neuroscience, including a differentiated long-acting injectable franchise

PARSIPPANY, N.J., Sept. 18,

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophren

Fri, 18 Sep 2026 16:30:00 -0400

In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of participants receiving TEV-'749 for ≥ 6 months met criteria for remission
Treatment switch analyses provide clinical insights into maintaining established therapeutic ranges of olanzapine when initiating TEV-'749 from existing regimens
Ahead of the Q4 FDA anticipated approval decision, the growing body of science around TEV-'749 demonstrates Teva’s commitment to patient-centered innovation in neuroscience, including a differentiated long-acting injectable franchise

PARSIPPANY, N.J., Sept. 18,